Sort
10,766 grants matching “checkpoint inhibitor”
Targeting the immunosuppressive adenosine-axis to overcome T-cell γc cytokine signaling blockade and enhance antitumor immunity in hepatocellular carcinoma
$378,246Yong Qin · University Of Texas El Paso · U54 · FY2025 · MD
The Role of Stromal Autophagy in Cutaneous Melanoma
$378,218Hilary A Coller · University Of California Los Angeles · R01 · FY2018 · CA
A novel more effective genotoxic therapy for ovarian cancer
$378,217Fiona Simpkins · University Of Pennsylvania · R37 · FY2024 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer
$378,030Worapol Ngamcherdtrakul · Pdx Pharmaceuticals, Inc. · R44 · FY2021 · CA
Project 3: Localized microneedle-directed combination immunotherapy for cSCC
$378,023Louis D Falo · University Of Pittsburgh At Pittsburgh · P50 · FY2022 · CA
Mechanisms of radioresistance and strategies for radiosensitization in OCCC
$377,816Guang Peng · University Of Tx Md Anderson Can Ctr · R01 · FY2016 · CA
Molecular Events Initiating B Cell Fate Determination
$377,750Kay Lynn Medina · Mayo Clinic Rochester · R01 · FY2011 · HL
Molecular Events Initiating B Cell Fate Determination
$377,750Kay Lynn Medina · Mayo Clinic Rochester · R01 · FY2010 · HL
Molecular Events Initiating B Cell Fate Determination
$377,750Kay Lynn Medina · Mayo Clinic Rochester · R01 · FY2009 · HL
Molecular Events Initiating B Cell Fate Determination
$377,750Kay Lynn Medina · Mayo Clinic Rochester · R01 · FY2012 · HL
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
$377,735Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
Role of exosomal SPHK1 in ovarian cancer progression
$377,679Sunila Pradeep · Medical College Of Wisconsin · R01 · FY2022 · CA
Replication Associated Genetic Rearrangements
$377,645Brandeis University · R01 · FY2005 · GM
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors
$377,573Everett Stone · University Of Texas At Austin · R01 · FY2020 · CA
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers
$377,516Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2024 · CA
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
$377,438Marka Crittenden · Providence Portland Medical Center · R01 · FY2020 · CA
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
$377,438Marka Crittenden · Providence Portland Medical Center · R01 · FY2018 · CA
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
$377,438Marka Crittenden · Providence Portland Medical Center · R01 · FY2017 · CA
Project 1: Promoting Graft-versus-Tumor Effects in the Bone Marrow
$377,415Geoffrey Roger Hill · Fred Hutchinson Cancer Research Center · P01 · FY2020 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$377,327Fumito Ito · University Of Southern California · R01 · FY2024 · CA
Checkpoints of TNF Gene Regulation
$377,234Anne Goldfeld · Immune Disease Institute, Inc. · R01 · FY2009 · GM
Control of Cell Fate and Proliferation in the Developing Eye
$377,219Utpal Banerjee · University Of California Los Angeles · R01 · FY2009 · EY
Control of Cell Fate and Proliferation in the Developing Eye
$377,219Utpal Banerjee · University Of California Los Angeles · R01 · FY2007 · EY
Nanoformulated small molecule immunotherapy for SHH medulloblastoma
$377,088Marina Sokolsky-Papkov · Univ Of North Carolina Chapel Hill · R01 · FY2024 · NS
Immunological, serologic, and imaging biomarker predictors of flare in pediatric spondyloarthritis
$377,034Pamela Fitch Weiss · Children'S Hosp Of Philadelphia · R01 · FY2024 · AR